Abstract
The aim of this study is to compare cost utility of Ocrelizimuab versus Fingolimod in relapsing-remitting multiple sclerosis (RRMS) from Ministry of Health payor perspective in Egypt.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
